Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Gets OK from Creditors for Reorganization Plan

NEW YORK (GenomeWeb News) – Vermillion today said that its unsecured creditors have "overwhelmingly accepted" its First Amended Chapter 11 Plan of Reorganization.

Approval of the plan clears the way for the Fremont, Calif.-based molecular diagnostics firm to proceed to a confirmation hearing for the plan before the US Bankruptcy Court for the District of Delaware. That confirmation hearing is scheduled for tomorrow, Jan. 7.

Vermillion filed for Chapter 11 bankruptcy protection on March 30, 2009, but stayed in business as it sought US Food and Drug Administration clearance for its OVA1 ovarian tumor triage diagnostic test, which the firm received in September.

The firm subsequently filed its plan of reorganization and disclosure statement with the US Bankruptcy Court in November.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.